硕世生物 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	350.0M	403.0M	5.5B	2.8B	1.7B
Revenue Growth %	-13.2%	-92.7%	95.0%	63.2%	--
Total Revenue	350.0M	403.0M	5.5B	2.8B	1.7B
Cost Of Revenue	132.0M	145.0M	2.2B	876.0M	390.0M
+Gross Profit	218.0M	258.0M	3.4B	2.0B	1.3B
Gross Margin %	62.3%	64.0%	60.6%	69.1%	77.6%
Total Operating Cost	409.0M	836.0M	3.5B	1.5B	838.0M
Selling Expenses	131.0M	200.0M	423.0M	417.0M	297.0M
Admin Expenses	82.6M	177.0M	297.0M	117.0M	67.1M
Rd Expenses	101.0M	136.0M	186.0M	107.0M	72.1M
Finance Expenses	-33.0M	-47.7M	-34.1M	-21.1M	-6.0M
+Operating Income	8.8M	-365.0M	2.1B	1.4B	963.0M
Operating Margin %	2.5%	-90.6%	38.8%	49.1%	55.3%
Non Operating Income	788,600	1.2M	244,800	43,700	19,100
Non Operating Expenses	5.4M	11.8M	11.2M	3.2M	2.0M
Investment Income	-1.4M	1.6M	3.6M	-2.7M	-685,000
Fair Value Change Income	2.2M	13.1M	48.1M	32.2M	19.9M
Asset Disposal Income	2.2M	3.9M	2.8M	3.3M	6.1M
Asset Impairment Loss	25.0M	187.0M	341.0M	3.6M	863,900
Other Income	65.5M	48.9M	43.3M	48.9M	35.7M
Income Before Tax	4.2M	-376.0M	2.1B	1.4B	961.0M
Income Tax	6.2M	-1.9M	311.0M	199.0M	141.0M
+Net Income	-2.0M	-374.0M	1.8B	1.2B	820.0M
Net Margin %	-0.6%	-92.8%	33.0%	42.0%	47.1%
Net Income Attributable	-2.0M	-374.0M	1.8B	1.2B	820.0M
Eps Basic	-0.03	-6.38	31.18	20.36	13.98
Eps Diluted	-0.03	-6.38	31.18	20.36	13.98

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	811.0M	1.8B	1.8B	1.3B	1.1B
Trading Financial Assets	1.1B	695.0M	1.0B	623.0M	298.0M
Accounts Receivable	53.8M	109.0M	564.0M	343.0M	157.0M
Notes Receivable	72,900	--	46.0M	1.0M	2.4M
Notes And Accounts Receivable	53.9M	109.0M	610.0M	344.0M	160.0M
Prepayments	18.0M	17.0M	29.5M	24.2M	14.3M
Inventory	67.0M	93.9M	236.0M	250.0M	163.0M
Total Current Assets	2.1B	2.7B	3.7B	2.5B	1.8B
Long Term Equity Investment	220.0M	113.0M	116.0M	22.7M	24.3M
Fixed Assets	--	596.0M	695.0M	680.0M	83.9M
Fixed Assets Total	558.0M	596.0M	695.0M	680.0M	83.9M
Construction In Progress	--	1.5M	17.0M	20.7M	239.0M
Construction In Progress Total	4.9M	1.5M	17.0M	20.7M	239.0M
Intangible Assets	27.4M	29.9M	27.4M	26.8M	26.6M
Long Term Deferred Expenses	34.6M	55.1M	74.2M	54.3M	25.6M
Total Non Current Assets	1.6B	1.2B	1.2B	960.0M	498.0M
Total Assets	3.7B	3.9B	4.9B	3.5B	2.3B
Short Term Borrowings	228.0M	157.0M	84.9M	150.0M	50.0M
Accounts Payable	23.9M	75.0M	433.0M	353.0M	109.0M
Advance Receipts	--	--	--	--	--
Contract Liabilities	38.8M	14.5M	38.4M	66.2M	50.2M
Total Current Liabilities	368.0M	364.0M	933.0M	856.0M	522.0M
Total Non Current Liabilities	121.0M	137.0M	180.0M	107.0M	90.7M
Total Liabilities	489.0M	501.0M	1.1B	963.0M	613.0M
Paid In Capital	56.7M	58.6M	58.6M	58.6M	58.6M
Capital Reserve	661.0M	807.0M	806.0M	806.0M	805.0M
Surplus Reserve	29.3M	29.3M	29.3M	29.3M	29.3M
Retained Earnings	2.5B	2.5B	2.9B	1.6B	772.0M
Equity Attributable	3.3B	3.4B	3.8B	2.5B	1.7B
Total Equity	3.3B	3.4B	3.8B	2.5B	1.7B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	473.0M	860.0M	5.5B	2.8B	1.8B
Tax Refunds Received	834,000	1.3M	28.4M	19.3M	15.1M
Total Operating Cash Inflow	580.0M	1.1B	5.6B	2.8B	1.9B
Cash Paid For Goods	75.8M	358.0M	2.2B	858.0M	482.0M
Cash Paid To Employees	211.0M	414.0M	550.0M	442.0M	140.0M
Taxes Paid	17.7M	117.0M	577.0M	351.0M	177.0M
Total Operating Cash Outflow	434.0M	1.2B	3.6B	1.9B	947.0M
Operating Cash Flow	146.0M	-113.0M	2.0B	986.0M	936.0M
Total Investing Cash Inflow	2.5B	2.9B	2.5B	1.5B	1.2B
Total Investing Cash Outflow	3.4B	2.4B	3.3B	2.2B	1.4B
Investing Cash Flow	-873.0M	462.0M	-718.0M	-749.0M	-260.0M
Cash From Borrowings	442.0M	314.0M	153.0M	150.0M	50.0M
Dividends And Interest Paid	7.1M	6.0M	591.0M	325.0M	176.0M
Debt Repayments	372.0M	242.0M	218.0M	50.0M	--
Total Financing Cash Inflow	442.0M	314.0M	153.0M	150.0M	50.0M
Total Financing Cash Outflow	537.0M	259.0M	821.0M	384.0M	176.0M
Financing Cash Flow	-94.8M	55.3M	-667.0M	-234.0M	-126.0M
Net Change In Cash	-821.0M	403.0M	580.0M	1.4M	549.0M
Ending Cash Balance	810.0M	1.6B	1.2B	647.0M	646.0M
Capex	62.9M	111.0M	351.0M	304.0M	135.0M